Complete remission of a primary cutaneous follicle-center cell lymphoma (EORTC criteria)/diffuse large B-cell lymphoma (WHO criteria) by single first-line therapy with rituximab [2]

Journal of Dermatology

Volumn 33, Issue 5, 2006, Pages 377-379

  Nagasaka, Akiko ^a   Matsue, Hiroyuki ^a   Kawamura, Tatsuyoshi ^a   Kanzaki, Mirei ^a   Inozume, Takashi ^a   Nakamura, Yuumi ^a   Shimizu, Akira ^a   Shibagaki, Naotaka ^a   Yanagi, Mitsuaki ^a   Shimada, Shinji ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD79A ANTIGEN; HLA DR ANTIGEN; RITUXIMAB; MONOCLONAL ANTIBODY;

AGED; CANCER CLASSIFICATION; CASE REPORT; CELL INFILTRATION; CHILL; DIFFERENTIAL DIAGNOSIS; DIFFUSE LARGE B CELL LYMPHOMA; DRUG EFFECT; DRUG EFFICACY; FEMALE; FEVER; FLUSHING; HEADACHE; HUMAN; HUMAN TISSUE; HYPERSENSITIVITY; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LETTER; LYMPHOID CELL; MUCOCUTANEOUS REACTION; NAUSEA; PRIMARY CUTANEOUS FOLLICLE CENTER CELL LYMPHOMA; SIDE EFFECT; SKIN BIOPSY; SKIN LYMPHOMA; SKIN MANIFESTATION; SUBCUTANEOUS NODULE; TUMOR LYSIS SYNDROME; AXILLA; B CELL LYMPHOMA; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; PATHOLOGY; SKIN TUMOR;

AGED; ANTIBODIES, MONOCLONAL; AXILLA; DIAGNOSIS, DIFFERENTIAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; SKIN NEOPLASMS;

EID: 33745314102     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2006.00088.x     Document Type: Letter

References (9)

1. Prince HM, Yap LM, Blum R et al. Primary cutaneous B-cell lymphomas. Clin Exp Dermatol 2003 28 : 8 12.
2. Smith BD, Glusac EJ, McNiff JM et al. Primary cutaneous B-cell lymphoma treated with radiotherapy: A comparison of the European Organization for Research and Treatment of Cancer and the WHO classification systems. J Clin Oncol 2004 22 : 634 639.
3. Kerl H, Kodama K, Cerroni L. Diagnostic principles and new developments in primary cutaneous B-cell lymphomas. J Dermatol Sci 2004 34 : 167 175.
4. Fink-Puches R, Wolf IH, Zalaudek I et al. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol 2005 52 : 847 853.
5. Lacouture ME, Baron JM, Jani AB et al. Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody. Clin Exp Dermatol 2005 30 : 46 48.
6. Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005 105 : 3768 3785.
7. Grillo-Lopez AJ, Hedrick E, Rashford M et al. Rituximab: Ongoing and future clinical development. Semin Oncol 2002 29 : 105 112.
8. Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: Present and promise. Crit Rev Oncol Hemat 2005 54 : 11 29.
9. Roguedas AM, Watier H, Paintaud G et al. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: Local and systemic efficacy in primary cutaneous B-cell lymphoma. Br J Dermatol 2005 152 : 541 544.